👍

港股异动 | 科济药业-B(02171)午前涨超12% 核心管线产品CT053在今年有望商业化

智通财经APP获悉,科济药业-B午前涨超12%,截至发稿,涨12.29%,报19.74港元,成交额8656.07万港元。据悉,科济药业核心管线产品为CT053,被开发用于治疗失败的复发或难治性多发性骨髓瘤成年患者,可特异性识别BCMA,令CAR-T细胞能够有效靶向及去除在细胞表面携带BCMA的多发性骨髓瘤细胞。2022年10月18日,CT053新药上市申请获国家药监局受理;此外,CT053在北美正开展Ib/II期临床试验,预计2023年递交BLA。分析表示,CT053在今年有望商业化。
港股异动 | 科济药业-B(02171)午前涨超12% 核心管线产品CT053在今年有望商业化

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

  • Top
  • Latest
empty
No comments yet